All in all anyone who looks past the headline can see those costs are temporary. The selloff will will provide another good entry point. They stopped the buyback when they knew the report will cause some selling.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
